Andrew Gabriel Herzog, M.D.,C.M.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epilepsy | 59 | 2021 | 3301 | 5.650 |
Why?
|
| Anticonvulsants | 40 | 2021 | 1914 | 4.630 |
Why?
|
| Menstrual Cycle | 19 | 2022 | 551 | 3.050 |
Why?
|
| Contraception | 6 | 2019 | 356 | 2.680 |
Why?
|
| Progesterone | 21 | 2015 | 773 | 2.440 |
Why?
|
| Seizures | 18 | 2023 | 2851 | 2.300 |
Why?
|
| Epilepsy, Reflex | 2 | 2023 | 26 | 1.710 |
Why?
|
| Contraceptive Agents | 4 | 2017 | 150 | 1.570 |
Why?
|
| Gonadal Steroid Hormones | 10 | 2021 | 711 | 1.510 |
Why?
|
| Sexual Dysfunction, Physiological | 9 | 2010 | 357 | 1.230 |
Why?
|
| Pregnancy, Unplanned | 2 | 2019 | 95 | 1.160 |
Why?
|
| Epilepsy, Temporal Lobe | 16 | 2009 | 403 | 1.100 |
Why?
|
| Epilepsies, Partial | 8 | 2011 | 436 | 1.050 |
Why?
|
| Registries | 7 | 2019 | 8077 | 0.910 |
Why?
|
| Ovulation | 5 | 2011 | 189 | 0.910 |
Why?
|
| Menstruation Disturbances | 10 | 2009 | 148 | 0.910 |
Why?
|
| Folic Acid | 2 | 2019 | 1300 | 0.790 |
Why?
|
| Valproic Acid | 5 | 2016 | 446 | 0.770 |
Why?
|
| Pituitary Diseases | 1 | 2021 | 141 | 0.700 |
Why?
|
| Endocrine System Diseases | 6 | 2007 | 248 | 0.690 |
Why?
|
| Polycystic Ovary Syndrome | 8 | 2002 | 369 | 0.670 |
Why?
|
| Reproduction | 5 | 2007 | 668 | 0.670 |
Why?
|
| Triazines | 5 | 2009 | 316 | 0.640 |
Why?
|
| Testosterone | 11 | 2010 | 2401 | 0.600 |
Why?
|
| Hypogonadism | 8 | 2010 | 798 | 0.580 |
Why?
|
| Vitamin B Complex | 1 | 2019 | 288 | 0.580 |
Why?
|
| Menarche | 2 | 2019 | 513 | 0.570 |
Why?
|
| Contraceptives, Oral, Combined | 2 | 2009 | 113 | 0.560 |
Why?
|
| Pregnanolone | 2 | 2014 | 62 | 0.520 |
Why?
|
| Contraceptive Agents, Female | 1 | 2017 | 135 | 0.510 |
Why?
|
| Contraception Behavior | 1 | 2017 | 184 | 0.510 |
Why?
|
| Epilepsy, Complex Partial | 5 | 2006 | 62 | 0.490 |
Why?
|
| Fertility | 1 | 2019 | 770 | 0.490 |
Why?
|
| Infertility, Female | 2 | 2019 | 784 | 0.480 |
Why?
|
| Abortion, Spontaneous | 1 | 2019 | 542 | 0.460 |
Why?
|
| Luteinizing Hormone | 10 | 2005 | 864 | 0.440 |
Why?
|
| Age of Onset | 2 | 2019 | 3266 | 0.430 |
Why?
|
| Adolescent | 38 | 2023 | 85649 | 0.430 |
Why?
|
| Premenstrual Syndrome | 2 | 2011 | 109 | 0.410 |
Why?
|
| Progestins | 3 | 2009 | 303 | 0.410 |
Why?
|
| Alcoholism | 1 | 2022 | 1904 | 0.400 |
Why?
|
| Kindling, Neurologic | 2 | 2002 | 30 | 0.390 |
Why?
|
| Clomiphene | 5 | 1998 | 72 | 0.390 |
Why?
|
| Estradiol | 11 | 2011 | 2021 | 0.380 |
Why?
|
| Circadian Rhythm | 3 | 2015 | 2623 | 0.380 |
Why?
|
| Female | 88 | 2023 | 379592 | 0.380 |
Why?
|
| Adult | 65 | 2023 | 213712 | 0.370 |
Why?
|
| Adrenal Hyperplasia, Congenital | 2 | 2001 | 98 | 0.360 |
Why?
|
| Sex Hormone-Binding Globulin | 3 | 2005 | 548 | 0.350 |
Why?
|
| Amygdala | 4 | 2002 | 1305 | 0.350 |
Why?
|
| Functional Laterality | 5 | 2009 | 2290 | 0.320 |
Why?
|
| Drug Interactions | 4 | 2017 | 1458 | 0.300 |
Why?
|
| Aromatase Inhibitors | 2 | 2010 | 491 | 0.300 |
Why?
|
| Young Adult | 14 | 2019 | 56350 | 0.290 |
Why?
|
| Estrogens | 5 | 2007 | 1562 | 0.290 |
Why?
|
| Luteal Phase | 4 | 2011 | 147 | 0.290 |
Why?
|
| Nervous System Physiological Phenomena | 1 | 2007 | 117 | 0.290 |
Why?
|
| Humans | 101 | 2023 | 742088 | 0.280 |
Why?
|
| Middle Aged | 40 | 2023 | 213127 | 0.270 |
Why?
|
| Ethynodiol Diacetate | 1 | 2005 | 5 | 0.270 |
Why?
|
| Steroids | 2 | 2011 | 931 | 0.260 |
Why?
|
| Ketoconazole | 3 | 2001 | 95 | 0.260 |
Why?
|
| Gonadotropin-Releasing Hormone | 5 | 2002 | 1185 | 0.260 |
Why?
|
| Testolactone | 2 | 1998 | 7 | 0.260 |
Why?
|
| Contraceptives, Oral, Hormonal | 2 | 2017 | 188 | 0.260 |
Why?
|
| Limbic System | 2 | 1999 | 426 | 0.250 |
Why?
|
| Endocrine Glands | 1 | 2005 | 103 | 0.250 |
Why?
|
| Gonadotropins, Pituitary | 2 | 2003 | 73 | 0.250 |
Why?
|
| Ethinyl Estradiol | 1 | 2005 | 116 | 0.250 |
Why?
|
| Nitriles | 1 | 2010 | 952 | 0.250 |
Why?
|
| Androgens | 3 | 2006 | 1271 | 0.240 |
Why?
|
| Triazoles | 1 | 2010 | 907 | 0.240 |
Why?
|
| Phenytoin | 6 | 2006 | 197 | 0.230 |
Why?
|
| Sexual Behavior | 2 | 2021 | 2050 | 0.220 |
Why?
|
| Follicular Phase | 3 | 2011 | 153 | 0.210 |
Why?
|
| Mood Disorders | 2 | 1999 | 1106 | 0.210 |
Why?
|
| Carbamazepine | 4 | 2006 | 229 | 0.200 |
Why?
|
| Sexual Dysfunctions, Psychological | 2 | 2006 | 187 | 0.200 |
Why?
|
| Electroencephalography | 12 | 2015 | 6142 | 0.200 |
Why?
|
| Hypothalamo-Hypophyseal System | 3 | 2009 | 703 | 0.200 |
Why?
|
| Pregnancy | 8 | 2019 | 29087 | 0.200 |
Why?
|
| Endocrine System | 1 | 2002 | 113 | 0.200 |
Why?
|
| Osteoporosis | 1 | 2011 | 1581 | 0.200 |
Why?
|
| Sex Characteristics | 3 | 2007 | 2585 | 0.200 |
Why?
|
| Paraneoplastic Endocrine Syndromes | 1 | 2000 | 31 | 0.190 |
Why?
|
| Hyperprolactinemia | 2 | 2000 | 129 | 0.190 |
Why?
|
| Leiomyomatosis | 1 | 2000 | 70 | 0.180 |
Why?
|
| Analysis of Variance | 4 | 2015 | 6365 | 0.170 |
Why?
|
| Migraine Disorders | 3 | 2007 | 1620 | 0.170 |
Why?
|
| Anovulation | 3 | 2011 | 58 | 0.170 |
Why?
|
| Glucocorticoids | 2 | 1999 | 2107 | 0.170 |
Why?
|
| Retrospective Studies | 9 | 2023 | 77098 | 0.170 |
Why?
|
| Genes, fos | 1 | 1998 | 183 | 0.160 |
Why?
|
| Hydrocortisone | 3 | 2001 | 1825 | 0.160 |
Why?
|
| Birth Rate | 1 | 2019 | 170 | 0.160 |
Why?
|
| Anxiety Disorders | 2 | 1999 | 2684 | 0.150 |
Why?
|
| Locus Coeruleus | 1 | 1998 | 176 | 0.150 |
Why?
|
| Hypothalamus | 3 | 2000 | 1063 | 0.150 |
Why?
|
| Neurons | 5 | 2007 | 9325 | 0.150 |
Why?
|
| Muscle Hypotonia | 1 | 1998 | 165 | 0.140 |
Why?
|
| Bromocriptine | 1 | 1997 | 111 | 0.140 |
Why?
|
| Saliva | 1 | 2001 | 805 | 0.140 |
Why?
|
| Cushing Syndrome | 1 | 1998 | 249 | 0.140 |
Why?
|
| Menopause | 3 | 2003 | 1621 | 0.140 |
Why?
|
| Pregnancy Rate | 1 | 2019 | 643 | 0.140 |
Why?
|
| Aggression | 1 | 2001 | 753 | 0.140 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 1998 | 369 | 0.140 |
Why?
|
| Menstruation | 3 | 2011 | 299 | 0.140 |
Why?
|
| Cluster Analysis | 1 | 2023 | 2713 | 0.130 |
Why?
|
| Risk | 2 | 2019 | 9679 | 0.130 |
Why?
|
| Live Birth | 1 | 2019 | 512 | 0.130 |
Why?
|
| Intrauterine Devices | 1 | 2017 | 122 | 0.130 |
Why?
|
| Male | 38 | 2021 | 349538 | 0.130 |
Why?
|
| Leiomyoma | 1 | 2000 | 728 | 0.130 |
Why?
|
| Antifungal Agents | 1 | 1999 | 729 | 0.120 |
Why?
|
| Age Distribution | 2 | 2019 | 2900 | 0.120 |
Why?
|
| Odds Ratio | 2 | 2017 | 9846 | 0.120 |
Why?
|
| Periodicity | 3 | 2009 | 363 | 0.120 |
Why?
|
| Radioimmunoassay | 1 | 2014 | 918 | 0.120 |
Why?
|
| Epilepsy, Generalized | 1 | 1995 | 174 | 0.110 |
Why?
|
| Drug Therapy, Combination | 8 | 2010 | 6483 | 0.110 |
Why?
|
| Prospective Studies | 7 | 2021 | 53187 | 0.110 |
Why?
|
| Iatrogenic Disease | 1 | 1996 | 545 | 0.110 |
Why?
|
| Torticollis | 1 | 1993 | 66 | 0.110 |
Why?
|
| Comorbidity | 4 | 2019 | 10372 | 0.110 |
Why?
|
| Sex | 1 | 1992 | 57 | 0.100 |
Why?
|
| Prolactin | 2 | 1992 | 669 | 0.100 |
Why?
|
| Neuropeptides | 1 | 1998 | 942 | 0.100 |
Why?
|
| Neural Inhibition | 2 | 2008 | 598 | 0.100 |
Why?
|
| Neuroendocrinology | 1 | 2011 | 6 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2015 | 10943 | 0.100 |
Why?
|
| Dehydroepiandrosterone | 3 | 2006 | 252 | 0.100 |
Why?
|
| Enzyme Inhibitors | 2 | 2003 | 3800 | 0.100 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2015 | 780 | 0.100 |
Why?
|
| Erectile Dysfunction | 3 | 1995 | 459 | 0.100 |
Why?
|
| Age Factors | 5 | 2017 | 18355 | 0.100 |
Why?
|
| Brain | 7 | 2011 | 26343 | 0.100 |
Why?
|
| Affect | 1 | 1999 | 1473 | 0.100 |
Why?
|
| Uterine Neoplasms | 1 | 2000 | 1513 | 0.100 |
Why?
|
| Income | 1 | 2019 | 1904 | 0.090 |
Why?
|
| Migraine with Aura | 1 | 2011 | 203 | 0.090 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 24913 | 0.090 |
Why?
|
| Statistics, Nonparametric | 2 | 2007 | 2885 | 0.090 |
Why?
|
| Ovariectomy | 1 | 2011 | 660 | 0.090 |
Why?
|
| Treatment Outcome | 8 | 2015 | 62966 | 0.080 |
Why?
|
| Pregnancy Complications | 3 | 2017 | 2861 | 0.080 |
Why?
|
| Injections, Intramuscular | 1 | 2010 | 548 | 0.080 |
Why?
|
| Hormone Replacement Therapy | 2 | 2006 | 744 | 0.080 |
Why?
|
| Double-Blind Method | 3 | 2012 | 12017 | 0.080 |
Why?
|
| Cerebrum | 1 | 2009 | 137 | 0.080 |
Why?
|
| Neurosecretory Systems | 1 | 1989 | 231 | 0.080 |
Why?
|
| Androstanes | 1 | 2006 | 21 | 0.070 |
Why?
|
| Severity of Illness Index | 4 | 2011 | 15530 | 0.070 |
Why?
|
| Gonadal Disorders | 1 | 2006 | 7 | 0.070 |
Why?
|
| Insurance, Health | 1 | 2019 | 2493 | 0.070 |
Why?
|
| Enzyme Induction | 1 | 2006 | 475 | 0.070 |
Why?
|
| United States | 4 | 2019 | 69693 | 0.070 |
Why?
|
| Sickness Impact Profile | 1 | 2007 | 304 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2023 | 21719 | 0.070 |
Why?
|
| Malformations of Cortical Development | 1 | 2008 | 200 | 0.070 |
Why?
|
| Biological Availability | 1 | 2006 | 396 | 0.070 |
Why?
|
| Quality of Life | 1 | 2007 | 12730 | 0.070 |
Why?
|
| Cerebral Cortex | 4 | 2008 | 5705 | 0.070 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2006 | 162 | 0.070 |
Why?
|
| Biological Clocks | 1 | 2008 | 322 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2002 | 8300 | 0.060 |
Why?
|
| Menorrhagia | 1 | 2005 | 63 | 0.060 |
Why?
|
| Central Nervous System Diseases | 1 | 1989 | 518 | 0.060 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2006 | 275 | 0.060 |
Why?
|
| Logistic Models | 2 | 2019 | 13403 | 0.060 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 3510 | 0.060 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2005 | 1431 | 0.060 |
Why?
|
| Reference Values | 3 | 2001 | 4982 | 0.060 |
Why?
|
| Dietary Supplements | 1 | 2017 | 3294 | 0.060 |
Why?
|
| Internet | 1 | 2017 | 3062 | 0.060 |
Why?
|
| Electrophysiology | 1 | 2007 | 1309 | 0.060 |
Why?
|
| Personality Inventory | 1 | 2007 | 1026 | 0.060 |
Why?
|
| Rats | 5 | 2002 | 24265 | 0.060 |
Why?
|
| Drug Combinations | 2 | 2006 | 1961 | 0.060 |
Why?
|
| Hypothalamus, Middle | 1 | 2002 | 25 | 0.060 |
Why?
|
| Forecasting | 2 | 2011 | 2948 | 0.060 |
Why?
|
| Electric Stimulation | 2 | 2005 | 1770 | 0.050 |
Why?
|
| Abdominal Pain | 1 | 1989 | 1059 | 0.050 |
Why?
|
| Kainic Acid | 1 | 2002 | 199 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2002 | 11363 | 0.050 |
Why?
|
| Drug Administration Schedule | 3 | 2001 | 4929 | 0.050 |
Why?
|
| Finasteride | 1 | 2003 | 89 | 0.050 |
Why?
|
| Women's Health | 2 | 2001 | 2034 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2008 | 2372 | 0.050 |
Why?
|
| Infertility | 1 | 2007 | 655 | 0.050 |
Why?
|
| Antidepressive Agents | 2 | 2006 | 2838 | 0.050 |
Why?
|
| Animals | 9 | 2009 | 168561 | 0.050 |
Why?
|
| Administration, Intravaginal | 2 | 1993 | 147 | 0.050 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 1999 | 238 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 40450 | 0.040 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2006 | 1202 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2011 | 2121 | 0.040 |
Why?
|
| Health Occupations | 1 | 2000 | 223 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 7901 | 0.040 |
Why?
|
| Aging | 3 | 2005 | 8626 | 0.040 |
Why?
|
| Sleep | 2 | 2008 | 4604 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2005 | 3001 | 0.040 |
Why?
|
| Bone Density | 1 | 2011 | 3469 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2007 | 6452 | 0.040 |
Why?
|
| Time Factors | 4 | 2015 | 40054 | 0.040 |
Why?
|
| Substantia Nigra | 1 | 1998 | 353 | 0.040 |
Why?
|
| Ovarian Cysts | 2 | 1988 | 115 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1998 | 648 | 0.030 |
Why?
|
| Sex Factors | 3 | 1999 | 10392 | 0.030 |
Why?
|
| Contraceptives, Oral | 2 | 2000 | 563 | 0.030 |
Why?
|
| Receptors, GABA-A | 1 | 1999 | 627 | 0.030 |
Why?
|
| Dementia | 3 | 1999 | 2501 | 0.030 |
Why?
|
| Follicle Stimulating Hormone | 2 | 1986 | 738 | 0.030 |
Why?
|
| Depression | 2 | 2007 | 7733 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2000 | 1206 | 0.030 |
Why?
|
| Electromyography | 1 | 1998 | 1391 | 0.030 |
Why?
|
| Prednisone | 1 | 1998 | 1567 | 0.030 |
Why?
|
| Paraneoplastic Syndromes | 1 | 1994 | 150 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 14720 | 0.030 |
Why?
|
| Uterine Cervical Diseases | 1 | 1993 | 77 | 0.030 |
Why?
|
| Amnesia | 1 | 1994 | 244 | 0.030 |
Why?
|
| Amenorrhea | 1 | 1996 | 485 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 15056 | 0.030 |
Why?
|
| Salpingectomy | 1 | 2011 | 52 | 0.030 |
Why?
|
| Motor Neuron Disease | 1 | 1992 | 106 | 0.030 |
Why?
|
| Libido | 1 | 1992 | 121 | 0.020 |
Why?
|
| Hormones | 1 | 1995 | 884 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2009 | 12695 | 0.020 |
Why?
|
| Models, Biological | 1 | 2007 | 9581 | 0.020 |
Why?
|
| Temporal Lobe | 1 | 1999 | 1669 | 0.020 |
Why?
|
| Menopause, Premature | 1 | 2011 | 132 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2000 | 2266 | 0.020 |
Why?
|
| Tumor Virus Infections | 1 | 1993 | 451 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 1990 | 332 | 0.020 |
Why?
|
| Gonadotropins | 1 | 1990 | 241 | 0.020 |
Why?
|
| Muscle Cramp | 1 | 1988 | 35 | 0.020 |
Why?
|
| Pituitary Hormone-Releasing Hormones | 1 | 1988 | 41 | 0.020 |
Why?
|
| Testicular Neoplasms | 1 | 1994 | 761 | 0.020 |
Why?
|
| Neural Pathways | 1 | 1998 | 2971 | 0.020 |
Why?
|
| Testis | 1 | 1990 | 800 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2000 | 3839 | 0.020 |
Why?
|
| Papillomaviridae | 1 | 1993 | 1118 | 0.020 |
Why?
|
| Nausea | 1 | 1989 | 665 | 0.020 |
Why?
|
| Mastectomy, Segmental | 1 | 1992 | 955 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2001 | 9144 | 0.020 |
Why?
|
| Prevalence | 2 | 2001 | 15194 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2000 | 3915 | 0.020 |
Why?
|
| Hysterectomy | 1 | 2011 | 927 | 0.020 |
Why?
|
| Radiotherapy | 1 | 1992 | 1525 | 0.020 |
Why?
|
| Climacteric | 1 | 2004 | 57 | 0.010 |
Why?
|
| Neuropsychological Tests | 2 | 1999 | 6974 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 1998 | 12958 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 18006 | 0.010 |
Why?
|
| Pelvis | 1 | 1988 | 730 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2000 | 7276 | 0.010 |
Why?
|
| Diarrhea | 1 | 1989 | 1343 | 0.010 |
Why?
|
| Reproductive History | 1 | 2003 | 209 | 0.010 |
Why?
|
| Population Surveillance | 1 | 1993 | 2616 | 0.010 |
Why?
|
| Placebos | 1 | 2006 | 1677 | 0.010 |
Why?
|
| Cognition | 1 | 1999 | 6722 | 0.010 |
Why?
|
| Papillomavirus Infections | 1 | 1993 | 1585 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1993 | 2011 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 1999 | 39004 | 0.010 |
Why?
|
| Breast | 1 | 1988 | 1958 | 0.010 |
Why?
|
| Ovary | 1 | 2003 | 981 | 0.010 |
Why?
|
| Pain | 2 | 1988 | 4961 | 0.010 |
Why?
|
| Wechsler Scales | 1 | 1999 | 260 | 0.010 |
Why?
|
| Mental Status Schedule | 1 | 1999 | 321 | 0.010 |
Why?
|
| Postmenopause | 1 | 2006 | 2461 | 0.010 |
Why?
|
| Irritable Mood | 1 | 1998 | 183 | 0.010 |
Why?
|
| Nerve Degeneration | 1 | 1980 | 748 | 0.010 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 1998 | 434 | 0.010 |
Why?
|
| Smoking | 1 | 1993 | 8969 | 0.010 |
Why?
|
| Congenital Abnormalities | 1 | 2000 | 707 | 0.010 |
Why?
|
| Sleep, REM | 1 | 1999 | 594 | 0.010 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 1998 | 503 | 0.010 |
Why?
|
| Needs Assessment | 1 | 2000 | 1146 | 0.010 |
Why?
|
| Abdomen | 1 | 1978 | 1107 | 0.010 |
Why?
|
| Serotyping | 1 | 1993 | 338 | 0.010 |
Why?
|
| Polysomnography | 1 | 1999 | 1772 | 0.010 |
Why?
|
| Mice | 1 | 1998 | 81045 | 0.010 |
Why?
|
| Bucladesine | 1 | 1990 | 121 | 0.010 |
Why?
|
| Leydig Cells | 1 | 1990 | 56 | 0.010 |
Why?
|
| Pericarditis | 1 | 1992 | 128 | 0.010 |
Why?
|
| Hydroxylation | 1 | 1990 | 141 | 0.010 |
Why?
|
| Rib Fractures | 1 | 1992 | 131 | 0.010 |
Why?
|
| Brachial Plexus | 1 | 1992 | 165 | 0.010 |
Why?
|
| Vaginal Smears | 1 | 1993 | 511 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1990 | 2191 | 0.010 |
Why?
|
| Aged | 5 | 2003 | 162944 | 0.010 |
Why?
|
| Antigens | 1 | 1994 | 1462 | 0.010 |
Why?
|
| Survivors | 1 | 1999 | 2286 | 0.010 |
Why?
|
| Chorionic Gonadotropin | 1 | 1990 | 474 | 0.000 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 1990 | 419 | 0.000 |
Why?
|
| Necrosis | 1 | 1992 | 1643 | 0.000 |
Why?
|
| Curriculum | 1 | 2000 | 3589 | 0.000 |
Why?
|
| Neck | 1 | 1992 | 693 | 0.000 |
Why?
|
| Carcinoma in Situ | 1 | 1993 | 802 | 0.000 |
Why?
|
| Blotting, Western | 1 | 1994 | 5180 | 0.000 |
Why?
|
| Recurrence | 1 | 1998 | 8333 | 0.000 |
Why?
|
| Autoantibodies | 1 | 1994 | 2036 | 0.000 |
Why?
|
| Lymph Node Excision | 1 | 1992 | 1248 | 0.000 |
Why?
|
| Urban Population | 1 | 1993 | 2018 | 0.000 |
Why?
|
| Radiation Injuries | 1 | 1992 | 1178 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 1992 | 20774 | 0.000 |
Why?
|
| Neoplasms, Second Primary | 1 | 1992 | 1052 | 0.000 |
Why?
|
| Longitudinal Studies | 1 | 1999 | 13921 | 0.000 |
Why?
|
| Health Surveys | 1 | 1993 | 4030 | 0.000 |
Why?
|
| Risk Factors | 2 | 2002 | 72145 | 0.000 |
Why?
|
| Aged, 80 and over | 2 | 1999 | 57683 | 0.000 |
Why?
|
| Combined Modality Therapy | 1 | 1992 | 8621 | 0.000 |
Why?
|
| Phosphorylation | 1 | 1990 | 8436 | 0.000 |
Why?
|
| Remission, Spontaneous | 1 | 1978 | 380 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2005 | 35342 | 0.000 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1993 | 4029 | 0.000 |
Why?
|
| Mass Screening | 1 | 1993 | 5238 | 0.000 |
Why?
|
| Alzheimer Disease | 1 | 1992 | 7988 | 0.000 |
Why?
|
| Child | 1 | 1998 | 77478 | 0.000 |
Why?
|